Athenex, Inc. (ATNX): Price and Financial Metrics

Athenex, Inc. (ATNX): $1.39

0.09 (+6.92%)

POWR Rating

Component Grades














  • ATNX scores best on the Growth dimension, with a Growth rank ahead of 87.56% of US stocks.
  • The strongest trend for ATNX is in Value, which has been heading down over the past 33 days.
  • ATNX ranks lowest in Quality; there it ranks in the 5th percentile.

ATNX Stock Summary

  • ATHENEX INC's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than merely 1.21% of US listed stocks.
  • With a price/sales ratio of 0.09, ATHENEX INC has a higher such ratio than only 1.82% of stocks in our set.
  • In terms of volatility of its share price, ATNX is more volatile than 99.43% of stocks we're observing.
  • Stocks that are quantitatively similar to ATNX, based on their financial statements, market capitalization, and price volatility, are KPTI, ALNY, DBX, GDDY, and ESPR.
  • ATNX's SEC filings can be seen here. And to visit ATHENEX INC's official web site, go to

ATNX Valuation Summary

  • ATNX's EV/EBIT ratio is -0.6; this is 109.16% lower than that of the median Healthcare stock.
  • ATNX's price/earnings ratio has moved up 7.8 over the prior 70 months.

Below are key valuation metrics over time for ATNX.

Stock Date P/S P/B P/E EV/EBIT
ATNX 2023-03-17 0.1 0.6 -0.1 -0.6
ATNX 2023-03-16 0.1 0.6 -0.1 -0.6
ATNX 2023-03-15 0.1 0.6 -0.1 -0.6
ATNX 2023-03-14 0.1 0.6 -0.1 -0.6
ATNX 2023-03-13 0.1 0.6 -0.1 -0.6
ATNX 2023-03-10 0.1 0.6 -0.1 -0.6

ATNX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ATNX has a Quality Grade of F, ranking ahead of 2.45% of graded US stocks.
  • ATNX's asset turnover comes in at 0.31 -- ranking 148th of 681 Pharmaceutical Products stocks.
  • XNCR, DRRX, and VRTX are the stocks whose asset turnover ratios are most correlated with ATNX.

The table below shows ATNX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.310 0.344 -0.445
2021-03-31 0.384 0.334 -0.479
2020-12-31 0.416 0.340 -0.548
2020-09-30 0.477 0.409 -0.574
2020-06-30 0.472 0.394 -0.716
2020-03-31 0.404 0.436 -0.726

ATNX Price Target

For more insight on analysts targets of ATNX, see our ATNX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $9.17 Average Broker Recommendation 1.71 (Moderate Buy)

ATNX Stock Price Chart Interactive Chart >

Price chart for ATNX

ATNX Price/Volume Stats

Current price $1.39 52-week high $23.80
Prev. close $1.30 52-week low $0.98
Day low $1.28 Volume 140,200
Day high $1.42 Avg. volume 122,633
50-day MA $3.05 Dividend yield N/A
200-day MA $6.16 Market Cap 12.04M

Athenex, Inc. (ATNX) Company Bio

Athenex Inc. is a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer. The company was founded in 2003 and is based in Buffalo, New York.

ATNX Latest News Stream

Event/Time News Detail
Loading, please wait...

ATNX Latest Social Stream

Loading social stream, please wait...

View Full ATNX Social Stream

Latest ATNX News From Around the Web

Below are the latest news stories about ATHENEX INC that investors may wish to consider to help them evaluate ATNX as an investment opportunity.

Athenex (ATNX) Upgraded to Buy: Here's Why

Athenex (ATNX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Yahoo | March 23, 2023

Athenex GAAP EPS of -$4.28, revenue of $25.06M

  • Athenex press release (NASDAQ:ATNX): Q4 GAAP EPS of -$4.28.
  • Revenue of $25.06M (+39.8% Y/Y).
  • Cash, cash equivalents, and restricted cash balance of $35.6 million 

Seeking Alpha | March 20, 2023

Athenex phase 1 neuroblastoma candidate trial hit by patient death; down 28%

  • KUR-501, an autologous CAR-NKT gene therapy in phase 1 from Athenex (NASDAQ:ATNX), has been placed in a clinical hold following an investigation into a patient death.
  • The company is also planning to conduct a safety risk mitigation.
  • The stock closed Monday down ~28%.
  • Athenex said the patient was heavily pretreated and died about three weeks after product administration.
  • The company is eying reopening the trial mid year. However, it conceded that there are "no assurances that the clinical hold will be lifted or when it will be lifted."

    Seeking Alpha | March 20, 2023

Athenex Provides Fourth Quarter and Full Year 2022 Financial Results and Business Update

Exploring a range of strategic alternatives Revenues from product sales from continued operations increased +27% Y/Y in 4Q 2022 and +33% for full year 2022 Net Loss attributable to Athenex was $34.2 million, or $4.28 per diluted share in 4Q2022, compared to $104.4 million, or $19.08 per diluted share, in the prior year quarter Cash, cash equivalents, and restricted cash balance of $35.6 million at year end Additional Phase 1 dose escalation study safety and preliminary efficacy data for KUR-502

Yahoo | March 20, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

It's time to start the day with an overview of the biggest pre-market stock movers worth keeping an eye on Thursday morning!

William White on InvestorPlace | February 16, 2023

Read More 'ATNX' Stories Here

ATNX Price Returns

1-mo -50.36%
3-mo -55.13%
6-mo -73.13%
1-year -92.31%
3-year -99.13%
5-year -99.55%
YTD -52.88%
2022 -89.15%
2021 -87.70%
2020 -27.57%
2019 20.33%
2018 -20.19%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9489 seconds.